Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Veterans Affairs Health Services Research and Development Service Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Clin Gastroenterol Hepatol. 2024 Sep;22(9):1858-1866.e4. doi: 10.1016/j.cgh.2024.04.006. Epub 2024 May 9.
BACKGROUND & AIMS: In patients with cirrhosis, continued heavy alcohol consumption and obesity may increase risk of hepatocellular carcinoma (HCC). We examined whether germline susceptibility to hepatic steatosis not only independently predisposes to HCC but may also act synergistically with other risk factors.
We analyzed data from 1911 patients in 2 multicenter prospective cohort studies in the United States. We classified patients according to alcohol consumption (current heavy vs not current heavy), obesity (body mass index ≥30 vs <30 kg/m2), and PNPLA3 I148M variant status (carrier of at least one G risk allele vs noncarrier). We examined the independent and joint effects of these risk factors on risk of developing HCC using Cox regression with competing risks.
Mean age was 59.6 years, 64.3% were male, 28.7% were Hispanic, 18.3% were non-Hispanic Black, 50.9% were obese, 6.2% had current heavy alcohol consumption, and 58.4% harbored at least 1 PNPLA3 G-allele. One hundred sixteen patients developed HCC. Compared with PNPLA3 noncarriers without heavy alcohol consumption, HCC risk was 2.65-fold higher (hazard ratio [HR], 2.65; 95% confidence interval [CI], 1.20-5.86) for carriers who had current heavy alcohol consumption. Compared with noncarrier patients without obesity, HCC risk was higher (HR, 2.40; 95% CI, 1.33-4.31) for carrier patients who were obese. PNPLA3 and alcohol consumption effect was stronger among patients with viral etiology of cirrhosis (HR, 3.42; 95% CI, 1.31-8.90). PNPLA3 improved 1-year risk prediction for HCC when added to a clinical risk model.
The PNPLA3 variant may help refine risk stratification for HCC in patients with cirrhosis with heavy alcohol consumption or obesity who may need specific preventive measures.
在肝硬化患者中,持续大量饮酒和肥胖可能会增加肝细胞癌(HCC)的风险。我们研究了肝脂肪变性的种系易感性是否不仅独立地使 HCC 易于发生,而且还可能与其他危险因素协同作用。
我们分析了来自美国 2 项多中心前瞻性队列研究的 1911 例患者的数据。我们根据饮酒情况(目前大量饮酒与非目前大量饮酒)、肥胖(体重指数≥30 与<30kg/m2)和 PNPLA3 I148M 变异状态(至少携带一个 G 风险等位基因与非携带者)对患者进行分类。我们使用竞争风险的 Cox 回归分析,检查这些危险因素对 HCC 发生风险的独立和联合作用。
平均年龄为 59.6 岁,64.3%为男性,28.7%为西班牙裔,18.3%为非西班牙裔黑人,50.9%肥胖,6.2%目前大量饮酒,58.4%至少携带 1 个 PNPLA3 G-等位基因。116 例患者发生 HCC。与非大量饮酒且不携带 PNPLA3 的患者相比,目前大量饮酒且携带 PNPLA3 的患者 HCC 风险高 2.65 倍(危险比[HR],2.65;95%置信区间[CI],1.20-5.86)。与非肥胖且不携带非携带者相比,肥胖且携带非携带者的患者 HCC 风险更高(HR,2.40;95%CI,1.33-4.31)。PNPLA3 和酒精消费效应在肝硬化病毒病因患者中更强(HR,3.42;95%CI,1.31-8.90)。当将 PNPLA3 添加到临床风险模型中时,PNPLA3 可改善 HCC 的 1 年风险预测。
PNPLA3 变异可能有助于对大量饮酒或肥胖的肝硬化患者进行 HCC 风险分层,这些患者可能需要特定的预防措施。